argenx SE (ARGNF)
OTCMKTS
· Delayed Price · Currency is USD
550.96
0.00 (0.00%)
At close: May 9, 2025
argenx SE Revenue
argenx SE had revenue of $807.37M in the quarter ending March 31, 2025, with 95.72% growth. This brings the company's revenue in the last twelve months to $2.64B, up 82.13% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
2.64B
Revenue Growth
+82.13%
P/S Ratio
12.81
Revenue / Employee
1.65M
Employees
1,599
Market Cap
33.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
argenx SE News
- 2 days ago - Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? - Benzinga
- 4 days ago - Argenx Q1 Earnings: Less Than Perfect Report Gets Punished - Seeking Alpha
- 4 days ago - Argenx targets Vision 2030 with 50,000 patients and 10 labeled indications by 2025 - Seeking Alpha
- 4 days ago - argenx SE (ARGX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Argenx plunges after Q1 revenue miss - Seeking Alpha
- 5 days ago - Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble - Investor's Business Daily
- 5 days ago - Earnings Scheduled For May 8, 2025 - Benzinga
- 5 days ago - Argenx reports mixed Q1 results; reaffirms FY25 outlook - Seeking Alpha